Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

NCT04712864 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

T-Cell Lymphoma
Peripheral T-Cell Lymphoma Refractory
Cutaneous T-Cell Lymphoma Refractory
Cutaneous T-Cell Lymphoma Recurrent
Peripheral T-Cell Lymphoma Recurrent

Interventions

BIOLOGICAL: LB1901

Sponsor

Legend Biotech USA Inc